~~<i id='EEF3D3AB60'><strike id='EEF3D3AB60'><tt id='EEF3D3AB60'><pre id='EEF3D3AB60'></pre></tt></strike></i>~~

Home» explore» leisure time

leisure time

author：leisure time 2025-10-07 02:56:11 Page View：83

A green number 3 with an eye is surrounded by smaller, black number 3s on a purple background — 3 to watch coverage from STAT — Christine Kao/STAT

Life in the CRISPR lane tends to move at lightning speed. This year saw the first-ever approval of a medicine based on the gene editing technology, barely more than a decade after publication of its first demonstration by Nobel laureates Jennifer Doudna and Emmanuelle Charpentier.

The landmark decision paves the way for in vivo therapies, which edit cells inside the body, to reach patients, as well as treatments based on more efficient genome editors with fancier DNA-altering tricks up their sleeves.

Here are three CRISPR developments we’re watching in 2024:

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Readout LOUD podcast: live from JPM 2024
Next article： Hollywood unions extend contract negotiations for actors

leisure time

Supreme Court strikes down use of affirmative action

ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

Heart disease and mental health: A look at cardiac psychology

MargeryQuackenbush,an85-year-oldpsychoanalyst,inherUpperEastSideapartmentinNewYork.OliviaFalcignofor

Tori Bowie and the unacceptable rates of Black maternal death

AlastairGrant/APThehorrorstoriesofBlackwomendyingorcomingclosetodeathinchildbirthneverseemtostopcomi

GSK to buy asthma

AdobeLONDON—GSKsaidTuesdayitwouldpurchasetheasthma-focuseddrugdeveloperAiolosBiofor$1billionupfront,